Andjela Kusic-Pajic
Actelion · Actelion Pharmaceuticals Australia Pty. Ltd
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andjela Kusic-Pajic as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:49 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT01223352 · Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial HypertensionActelion · completed · Pulmonary Arterial Hypertension · study director
- Ph2NCT01009177 · Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)Actelion · completed · Melanoma · study director
- Ph3NCT00319020 · Bosentan in Children With Pulmonary Arterial Hypertension Extension StudyActelion · completed · Pulmonary Arterial Hypertension · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:49 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- 695 citationsRCR 20.0
- Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study.Br J Clin Pharmacol · 200984 citationsRCR 2.6
- 69 citationsRCR 3.8
- Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.Int J Cardiol · 201449 citationsRCR 1.9
- FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion.Int J Cardiol · 201631 citationsRCR 1.3
- A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3.Br J Clin Pharmacol · 201724 citationsRCR 1.0
- Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis.Eur J Clin Pharmacol · 201216 citationsRCR 0.5